GATC Biotech Sequences Pediatric Brain Tumors for the International Cancer Genome Consortium
News May 18, 2010
GATC Biotech to sequence samples from brain tumors in children for the world’s largest cancer research project. The aim of the German PedBrainTumor Consortium within the ICGC is to develop diagnostic methods and treatments in order to be able to provide children with therapies which have fewer side effects in future.
GATC Biotech sequences genomes from tumor tissues and the corresponding controls from healthy samples of the same patients. It uses sequencing technologies from Illumina Inc., including the new Illumina HiSeq 2000. This instrument is currently the most efficient sequencing system with up to 200 gigabases per run.
The complete genomes are sequenced with a 30-fold coverage to ensure reliable data assessment. The data will be supplied to the DKFZ in fall 2010. The order value is Euro 750,000.
“Brain tumors are the main cause of cancer deaths in childhood. Therapies with few side effects are urgently required to make it easier for the children to bear the taxing treatment. The PedBrainTumor Project will bring us a great deal further forward in the development of such therapies. GATC Biotech proved itself to be a reliable sequencing partner in the pilot phase of the project and so we are now continuing that successful collaboration,” comments Professor Peter Lichter, project leader and spokesman of the German ICGC group.
“We are fully aware of the importance of this project and our responsibility. We are very proud to be allowed to support the DKFZ within the framework of the PedBrainTumor project,” says Peter Pohl, CEO of GATC Biotech.
The PedBrainTumor Consortium, a German contribution to the International Cancer Genome Consortium (ICGC), will receive Euro 15 million from the German Federal Ministry for Education and Research (BMBF) and German Cancer Aid (Deutsche Krebshilfe e.V.) over five years.
The project is managed by the German Cancer Research Center (DKFZ) and will investigate the molecular genetic causes of pediatric brain tumors. The scientists expect the results to provide starting points for new innovative therapies.
Mechanism Controlling Multiple Sclerosis Risk IdentifiedNews
Researchers at Karolinska Institutet have now discovered a new mechanism of a major risk gene for multiple sclerosis (MS) that triggers disease through so-called epigenetic regulation. They also found a protective genetic variant that reduces the risk for MS through the same mechanism.
Synthetic DNA Shuffling Enzyme Outpaces Natural CounterpartNews
A new synthetic enzyme, crafted from DNA rather than protein, flips lipid molecules within the cell membrane, triggering a signal pathway that could be harnessed to induce cell death in cancer cells. Researchers say their lipid-scrambling DNA enzyme is the first in its class to outperform naturally occurring enzymes – and does so by three orders of magnitudeREAD MORE
Antarctic Worm and Machine Learning Help Identify Cerebral Palsy EarlierNews
A research team has released a study in the peer-reviewed journal BMC Bioinformatics showing that DNA methylation patterns in circulating blood cells can be used to help identify spastic cerebral palsy (CP) patients. The technique which makes use of machine learning, data science and even analysis of Antarctic worms, raises hopes for earlier targeted CP therapies.